Technical Analysis for PRPO - Precipio, Inc.

Grade Last Price % Change Price Change
F 6.00 -2.28% -0.14
PRPO closed down 2.28 percent on Wednesday, November 20, 2024, on 1.18 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Stochastic Reached Oversold Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -2.28%
Slingshot Bearish Bearish Swing Setup -2.28%
200 DMA Support Bullish -2.28%
Pocket Pivot Bullish Swing Setup -2.28%

   Recent Intraday Alerts

Alert Time
200 DMA Support about 22 hours ago
Down 2 % about 22 hours ago
Down 1% about 22 hours ago
Possible Pocket Pivot 2 days ago
200 DMA Support 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Precipio, Inc. Description

Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Disease Natural Sciences Treatment Of Cancer Molecular Biology Genomics Molecular Diagnostics Analytical Services Laboratory Services Personalized Medicine Laboratory Techniques Polymerase Chain Reaction Pharmacogenomics Molecular Technologies

Is PRPO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.38
52 Week Low 4.31
Average Volume 7,582
200-Day Moving Average 6.05
50-Day Moving Average 6.46
20-Day Moving Average 6.24
10-Day Moving Average 6.18
Average True Range 0.29
RSI (14) 41.86
ADX 15.58
+DI 18.06
-DI 20.34
Chandelier Exit (Long, 3 ATRs) 5.83
Chandelier Exit (Short, 3 ATRs) 6.85
Upper Bollinger Bands 6.51
Lower Bollinger Band 5.97
Percent B (%b) 0.06
BandWidth 8.79
MACD Line -0.10
MACD Signal Line -0.08
MACD Histogram -0.0136
Fundamentals Value
Market Cap 8.52 Million
Num Shares 1.42 Million
EPS -7.47
Price-to-Earnings (P/E) Ratio -0.80
Price-to-Sales 0.67
Price-to-Book 0.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.29
Resistance 3 (R3) 6.31 6.24 6.24
Resistance 2 (R2) 6.24 6.17 6.23 6.22
Resistance 1 (R1) 6.12 6.12 6.10 6.10 6.21
Pivot Point 6.05 6.05 6.04 6.04 6.05
Support 1 (S1) 5.93 5.98 5.91 5.91 5.79
Support 2 (S2) 5.86 5.93 5.85 5.78
Support 3 (S3) 5.74 5.86 5.76
Support 4 (S4) 5.72